Overview: 5-Amino-Levulinic Acid TestIntroduction: The 5-Amino-Levulinic Acid Test measures 5-aminolevulinic acid (5-ALA), a compound involved in heme production, to diagnose porphyrias, rare disorders causing skin sensitivity, abdominal pain, or neurological issues due to defective heme synthesis. Aligned with 2023 American Academy of Neurology guidelines, it uses chromatography for high sensitivity, enabling accurate detection of porphyrias like acute intermittent porphyria. This test is crucial for confirming these conditions, guiding treatments like hemin, and preventing acute attacks, improving outcomes in metabolic and neurological health.
Other Names: 5-ALA Assay, Aminolevulinic Acid Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards.
Historical Milestone: 5-ALA was linked to porphyrias in the 1950s. Chromatography-based testing emerged in the 1970s, and by the 2000s, high-performance liquid chromatography (HPLC) improved specificity for porphyria diagnosis.
Purpose: Diagnoses porphyrias, guides treatment, and monitors for acute attacks in patients with symptoms like skin sensitivity or abdominal pain.
Test Parameters: 1. 5-Aminolevulinic Acid
Pretest Condition: No fasting required. Collect urine or plasma at symptom onset. Report skin sensitivity, abdominal pain, or neurological symptoms. Protect samples from light to prevent degradation.
Specimen: 5-20 mL urine (sterile container) or 2-4 mL plasma (EDTA). Transport in a biohazard bag within 2 hours, protected from light.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen, as 5-ALA may degrade.
Medical History: Document skin sensitivity, abdominal pain, neurological issues, or family history of porphyrias. Include medications or alcohol use that may trigger attacks.
Consent: Written consent is required, explaining the test's purpose, diagnostic implications, and potential treatment needs.
Procedural Considerations: Employs chromatography (HPLC) to measure 5-ALA levels. Results are available in 1-2 days, supporting rapid diagnosis.
Factors Affecting Result Accuracy: Light exposure or improper storage can degrade 5-ALA, causing false negatives. Medications like barbiturates may elevate levels, leading to false positives.
Clinical Significance: Elevated 5-ALA levels confirm porphyria, prompting therapy. Normal levels may require porphobilinogen or genetic testing for confirmation.
Specialist Consultation: Consult a neurologist or metabolic specialist for result interpretation. Genetic counseling is advised for familial porphyrias.
Additional Supporting Tests: Porphobilinogen, porphyrin levels, or genetic testing to confirm porphyria subtype.
Test Limitations: False negatives may occur during remission. Clinical correlation is needed to distinguish porphyria types.
References: AAN Porphyria Guidelines, 2023; Anderson KE, New England Journal of Medicine, 2022.
